Heparin and low molecular weight heparin in thrombosis and inflammation. emerging links

Chemistry and Biology of Heparin and Heparan Sulfate

Volumn , Issue , 2005, Pages 571-581

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649505791     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008044859-6/50021-6     Document Type: Chapter

References (55)

1. Weitz JI Low-molecular-weight heparin. N Engl J Med 1997, 337:688-698.
2. Mousa SA, Fareed JW Advances in anticoagulant, antithrombotic and thrombolytic drugs. Exp Opin Invest Drugs 2001, 10:157-162.
3. Mousa SA Comparative efficacy among different low molecular weight heparin (LMWHs) & drug interaction: implications in the management of vascular disorders. Thromb Haemost 2000, 26(Suppl 1):39-46.
4. Aguilar D, Goldhaber SZ Clinical uses of low molecular weight heparin. Chest 1999, 115:1418-1423.
5. Taheri SA, Lazar L, Haddad G, Castaldo R, Wilson M, Mousa S Diagnosis of deep venous thrombosis by use of soluble necrosis factor receptor. Angiology 1998, 49:537-541.
6. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993, 82:3253-3258.
7. Lantz M, Thysell H, Nilsson E, Olsson I On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991, 88:2026-2031.
8. Tyrell DJ, Kilfeather S, Page CP Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995, 16:198-204.
9. Hocking D, Ferro TJ, Johnson A Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992, 72:179-185.
10. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliott KT Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998, 9:274-281.
11. Meyer J, Cox CS, Herndon DN, Nakazawa H, Lentz CW, Traber LD, Traber DL Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993, 21:84-89.
12. Hiebert LM, Liu JM Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 1990, 83:47-51.
13. Matzner Y, Marx G, Drexler R, Eldor A The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984, 52:134-137.
14. Bazzoni G, Beltran Nunez A, Mascellani G, Bianchini P, Dejana E, Del Maschio A Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 1993, 121:268-275.
15. Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP, LaMicela M, D'amico L, Crimi N Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 2001, 108:703-708.
16. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, Sterk PJ Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996, 153:1790-1795.
17. Garrigo J, Danta I, Ahmed T Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 1996, 153:1702-1707.
18. Gaffney A, Gaffney P Rheumatoid arthritis and heparin. Br J Rheumatol 1996, 35:808.
19. Bowler SD, Smith SM, Lavercombe PS Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993, 147:160-163.
20. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM Sticky neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995, 37:585-588.
21. Petitou M, Hérault J-P, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999, 398:417-422.
22. Tyrrel DJ, Horne AP, Holme KR, Preuss JMH, Page CP Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
23. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, Panes J Heparin attenuates TNF-α induced inflammatory response through a CD11b dependent mechanism. Gut 2000, 47:88-96.
24. Panés J, Perry M, Granger DN Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999, 126:537-550.
25. Lever R, Hoult JRS, Page CP The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol 2000, 129:533-540.
26. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995, 90:220-223.
27. Gaffney P, Gaffney A Heparin therapy in refractory ulcerative colitis-an update. Gastroenterology 1996, 110:A913.
28. Evans RC, Rhodes JM Treatment of corticosteroid-resistant ulcerative colitis with heparin. A report of nine cases. Gut 1995, 37:A49.
29. Brazier F, Dupas JL Medical management of severe acute colitis. Rev Prat 1998, 48:1165-1167.
30. Malhotra S, Bhasin D, Shafiq N, Pandhi P Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opin Pharmacother 2004, 5:329-334.
31. Prajapati DN, Newcomer JR, Emmons J, Abu-Hajir M, Binion DG Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis 2002, 8:192-195.
32. He SH Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004, 10(3):309-318.
33. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995, 37:585-588.
34. Teixeira MM, Hellewell PG Suppression by intradermal administration of heparin of eosinophil accumulation but not edema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 1993, 110:1496-1500.
35. Carr J The anti-inflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Thromb Res 1979, 16:507-516.
36. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998, 101:877-889.
37. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 1995, 130:1473-1482.
38. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, el Khoury J, Cai TQ, Stein CA Mac-1 (CD11b/CD18) is an oligodeoxy-nucleotide-binding protein. Nat Med 1997, 3:414-420.
39. Emmanuele RM, Fareed J The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987, 48:591-596.
40. Brieger D, Dawes J Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997, 77:317-322.
41. Mousa SA, Mohamed S Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004, 92:627-633.
42. Mousa SA, Kaiser B Tissue factor pathway inhibitor in thrombosis and beyond: role of heparin. Drugs Future 2004, 29:751-766.
43. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988, 14:18-27.
44. Sutor AH, Massicotte P, Leaker M, Andrew M Heparin therapy in pediatric patients. Semin Thromb Hemost 1997, 23:303-319.
45. Majerus P, Broze JG, Miletich J Anticoagulant, thrombolytic and antiplatelet drugs. Goodman & Gilman's, The Pharmacological Basis of Therapeutics 1996, 1341-1359. McGraw-Hill, New York. 9th ed. J. Hardman, L. Limbird, P. Molinoff, R. Ruddon, A. Goodman (Eds.).
46. Silverstein R Drugs affecting hemostosis. Munson's Principles of Pharmacology 1995, 1123-1143. Chapman & Hall, New York. P. Munson, R. Mueller, G. Breeze (Eds.).
47. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88:2045-2048.
48. Itoh K, Nakao A, Kishimoto W, Takagi H Heparin effects on superoxide production by neutrophils. Eur Surg Res 1995, 27:184-188.
49. Attanasio M, Gori AM, Giusti B, Pepe G, Comeglio P, Brunelli T, Prisco D, Abbate R, Gensini GF, Neri Serneri GG Cytokine gene expression in human LPS- and IFN-gamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998, 79:959-962.
50. Dandona P, Qutob T, Hamouda W, Bakri F, Aljada A, Kumbkarni Y Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res 1999, 96:437-443.
51. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994, 75:701-710.
52. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995, 29:629-636.
53. Lucchesi BR, Kilgore KS Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 1997, 38:27-42.
54. Hawari FI, Shykoff BE, Izzo JL Heparin attenuates norepinephrine-induced venoconstriction. Vasc Med 1998, 3:95-100.
55. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbroner MA, Shin WS, Liao JK Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest 1995, 96:60-68.